Scott T. Rottinghaus - Feb 12, 2024 Form 4 Insider Report for ENANTA PHARMACEUTICALS INC (ENTA)

Role
Chief Medical Officer
Signature
/s/ Nathaniel S. Gardiner as attorney-in-fact
Stock symbol
ENTA
Transactions as of
Feb 12, 2024
Transactions value $
-$9,370
Form type
4
Date filed
2/14/2024, 08:15 PM
Previous filing
Dec 6, 2023
Next filing
Jul 15, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ENTA Common Stock Award $0 +2.58K +9.73% $0.00 29K Feb 12, 2024 Direct F1
transaction ENTA Common Stock Tax liability -$9.37K -755 -2.6% $12.41 28.3K Feb 12, 2024 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of Enanta common stock issued under performance share units ("PSUs") that vested as a result of performance against two-year research and development milestones in the calendar 2022-2023 period as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2024.
F2 Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU awards.